propofol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2302 2078-54-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propofol
  • ampofol
  • diprivan
  • disoprofol
  • pofol
An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
  • Molecular weight: 178.28
  • Formula: C12H18O
  • CLOGP: 3.93
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 20.23
  • ALOGS: -3.05
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.16 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 14.02 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 4.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 36 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 2, 1989 FDA FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1340.53 58.76 281 3367 4005 2350432
Hypotension 1177.21 58.76 382 3266 32054 2322383
Propofol infusion syndrome 767.06 58.76 104 3544 10 2354427
Bronchospasm 698.65 58.76 155 3493 2869 2351568
Cardiac arrest 619.85 58.76 196 3452 14734 2339703
Anaphylactic reaction 501.89 58.76 151 3497 9554 2344883
Bradycardia 429.78 58.76 135 3513 9846 2344591
Circulatory collapse 380.94 58.76 99 3549 3621 2350816
Tachycardia 375.09 58.76 138 3510 16271 2338166
Delayed recovery from anaesthesia 327.20 58.76 53 3595 139 2354298
Oxygen saturation decreased 323.67 58.76 102 3546 7484 2346953
Metabolic acidosis 269.72 58.76 84 3564 5914 2348523
Respiratory depression 267.40 58.76 67 3581 2103 2352334
Hyperthermia malignant 254.57 58.76 42 3606 128 2354309
Rhabdomyolysis 228.15 58.76 76 3572 6628 2347809
Shock 226.74 58.76 67 3581 3937 2350500
Blood pressure decreased 226.60 58.76 82 3566 9154 2345283
Erythema 220.01 58.76 107 3541 25052 2329385
Stress cardiomyopathy 199.47 58.76 49 3599 1412 2353025
Ventricular fibrillation 198.35 58.76 53 3595 2148 2352289
Acute kidney injury 197.15 58.76 103 3545 28019 2326418
Pulseless electrical activity 195.65 58.76 45 3603 970 2353467
Multiple organ dysfunction syndrome 191.70 58.76 69 3579 7572 2346865
Exposure during pregnancy 181.38 58.76 94 3554 25125 2329312
Drug ineffective 180.12 58.76 158 3490 101466 2252971
Status epilepticus 178.35 58.76 50 3598 2428 2352009
Hypoxia 174.27 58.76 61 3587 6166 2348271
Drug interaction 174.04 58.76 96 3552 29067 2325370
Post procedural complication 169.66 58.76 50 3598 2904 2351533
Maternal exposure during pregnancy 162.98 58.76 74 3574 14789 2339648
Seizure 155.48 58.76 84 3564 24382 2330055
Procedural complication 154.57 58.76 38 3610 1097 2353340
Haemodynamic instability 148.11 58.76 37 3611 1142 2353295
Pyrexia 144.79 58.76 107 3541 53601 2300836
Rash 141.46 58.76 110 3538 59448 2294989
Toxicity to various agents 140.28 58.76 87 3561 32667 2321770
Ventricular tachycardia 138.66 58.76 43 3605 2968 2351469
Oliguria 138.10 58.76 36 3612 1321 2353116
Dystonia 134.16 58.76 39 3609 2155 2352282
Respiratory arrest 129.81 58.76 49 3599 6129 2348308
Apnoea 122.46 58.76 33 3615 1378 2353059
Cardio-respiratory arrest 121.01 58.76 52 3596 9094 2345343
Myoclonus 120.83 58.76 37 3611 2446 2351991
Medication error 119.36 58.76 46 3602 6085 2348352
Respiratory failure 116.34 58.76 57 3591 13471 2340966
Intestinal ischaemia 116.13 58.76 30 3618 1061 2353376
Urticaria 115.47 58.76 69 3579 24192 2330245
Chills 114.57 58.76 59 3589 15493 2338944
Procedural hypotension 111.69 58.76 22 3626 216 2354221
Hepatitis 110.85 58.76 44 3604 6293 2348144
Sinus tachycardia 110.21 58.76 37 3611 3288 2351149
Anaesthetic complication 108.43 58.76 24 3624 431 2354006
Generalised tonic-clonic seizure 107.04 58.76 41 3607 5331 2349106
Unwanted awareness during anaesthesia 105.89 58.76 17 3631 41 2354396
Agitation 105.40 58.76 50 3598 11001 2343436
Blood creatine phosphokinase increased 105.21 58.76 40 3608 5096 2349341
Arteriospasm coronary 103.79 58.76 25 3623 660 2353777
Product contamination 99.80 58.76 20 3628 216 2354221
Transmission of an infectious agent via product 99.60 58.76 17 3631 67 2354370
Carcinoid crisis 97.12 58.76 15 3633 25 2354412
Anaphylactoid reaction 95.59 58.76 25 3623 928 2353509
Atrioventricular block complete 90.27 58.76 26 3622 1388 2353049
Septic shock 86.39 58.76 38 3610 7016 2347421
Hyperkalaemia 86.20 58.76 36 3612 5857 2348580
Unresponsive to stimuli 85.75 58.76 34 3614 4842 2349595
Depressed level of consciousness 83.65 58.76 38 3610 7566 2346871
Cardiogenic shock 83.64 58.76 28 3620 2463 2351974
Labile blood pressure 83.03 58.76 17 3631 206 2354231
Tryptase increased 82.89 58.76 14 3634 51 2354386
Hypertriglyceridaemia 82.67 58.76 22 3626 874 2353563
Anaphylactoid shock 81.69 58.76 15 3633 97 2354340
Hepatocellular injury 80.94 58.76 31 3617 4024 2350413
Diabetes insipidus 79.47 58.76 18 3630 360 2354077
Coma 77.32 58.76 38 3610 9018 2345419
Premature delivery 76.78 58.76 28 3620 3172 2351265
Arrhythmia 75.51 58.76 33 3615 5995 2348442
Airway complication of anaesthesia 75.01 58.76 12 3636 28 2354409
Anaesthetic complication pulmonary 72.97 58.76 11 3637 14 2354423
Drug use disorder 69.23 58.76 16 3632 351 2354086
Renal failure 68.85 58.76 44 3604 17305 2337132
Completed suicide 68.14 58.76 47 3601 20987 2333450
Laryngospasm 68.07 58.76 18 3630 697 2353740
Encephalopathy 67.14 58.76 28 3620 4533 2349904
Toxic epidermal necrolysis 66.21 58.76 25 3623 3119 2351318
Lactic acidosis 66.17 58.76 29 3619 5301 2349136
Aspartate aminotransferase increased 65.48 58.76 38 3610 12574 2341863
Hepatitis C 63.60 58.76 20 3628 1441 2352996
Vomiting 63.36 58.76 77 3571 71525 2282912
Intra-abdominal pressure increased 63.23 58.76 10 3638 21 2354416
Dyskinesia 62.53 58.76 27 3621 4762 2349675
Cyanosis 62.31 58.76 24 3624 3161 2351276
Alanine aminotransferase increased 61.73 58.76 38 3610 13994 2340443
Acute respiratory distress syndrome 61.54 58.76 24 3624 3268 2351169
Mitochondrial DNULL mutation 61.37 58.76 9 3639 8 2354429
Electrocardiogram ST segment elevation 61.34 58.76 16 3632 587 2353850
Disseminated intravascular coagulation 61.13 58.76 24 3624 3326 2351111
Hepatorenal failure 60.44 58.76 12 3636 123 2354314
Delirium 60.28 58.76 27 3621 5196 2349241
Foetal growth restriction 59.77 58.76 18 3630 1122 2353315
Stridor 59.64 58.76 16 3632 655 2353782
Pneumatosis 59.27 58.76 11 3637 76 2354361
Stevens-Johnson syndrome 58.86 58.76 25 3623 4234 2350203

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Propofol infusion syndrome 1232.93 60.28 176 3094 15 1743496
Hypotension 944.79 60.28 350 2920 29304 1714207
Anaphylactic shock 895.12 60.28 202 3068 2697 1740814
Rhabdomyolysis 667.96 60.28 212 3058 10878 1732633
Cardiac arrest 661.90 60.28 230 3040 15700 1727811
Anaphylactic reaction 552.43 60.28 160 3110 5953 1737558
Bradycardia 474.55 60.28 162 3108 10372 1733139
Hyperthermia malignant 426.14 60.28 76 3194 253 1743258
Bronchospasm 389.41 60.28 97 3173 1985 1741526
Delayed recovery from anaesthesia 329.49 60.28 54 3216 88 1743423
Oxygen saturation decreased 317.55 60.28 103 3167 5572 1737939
Tachycardia 315.24 60.28 126 3144 12502 1731009
Metabolic acidosis 302.02 60.28 98 3172 5304 1738207
Circulatory collapse 282.64 60.28 84 3186 3383 1740128
Ventricular fibrillation 260.86 60.28 75 3195 2681 1740830
Chills 255.11 60.28 106 3164 11581 1731930
Erythema 228.95 60.28 104 3166 14084 1729427
Blood creatine phosphokinase increased 226.30 60.28 90 3180 8766 1734745
Blood pressure decreased 203.30 60.28 80 3190 7566 1735945
Shock 198.32 60.28 67 3203 4094 1739417
Post procedural complication 190.91 60.28 57 3213 2323 1741188
Ventricular tachycardia 176.42 60.28 60 3210 3738 1739773
Drug interaction 175.22 60.28 109 3161 27849 1715662
Anaesthetic complication 164.09 60.28 33 3237 235 1743276
Pyrexia 157.21 60.28 124 3146 46276 1697235
Electrocardiogram ST segment elevation 151.90 60.28 39 3231 897 1742614
Respiratory arrest 151.25 60.28 60 3210 5779 1737732
Pulseless electrical activity 139.01 60.28 37 3233 983 1742528
Hyperkalaemia 135.50 60.28 62 3208 8485 1735026
Cardio-respiratory arrest 133.62 60.28 63 3207 9230 1734281
Agitation 129.24 60.28 65 3205 10961 1732550
Respiratory depression 122.18 60.28 40 3230 2207 1741304
Acute kidney injury 121.55 60.28 95 3175 34849 1708662
Hypoxia 119.45 60.28 51 3219 5912 1737599
Procedural complication 117.28 60.28 33 3237 1083 1742428
Drug ineffective 115.72 60.28 120 3150 63681 1679830
Hypoxic-ischaemic encephalopathy 110.43 60.28 30 3240 862 1742649
Lactic acidosis 109.81 60.28 46 3224 5083 1738428
Laryngospasm 109.00 60.28 25 3245 350 1743161
Cyanosis 103.87 60.28 37 3233 2637 1740874
Status epilepticus 101.53 60.28 34 3236 2012 1741499
Seizure 96.72 60.28 67 3203 20374 1723137
Toxicity to various agents 96.41 60.28 77 3193 29064 1714447
Pulmonary oedema 95.66 60.28 45 3225 6541 1736970
Transmission of an infectious agent via product 93.75 60.28 17 3253 63 1743448
Drug use disorder 93.49 60.28 23 3247 441 1743070
Ventricular arrhythmia 93.14 60.28 25 3245 685 1742826
Foetal exposure during pregnancy 87.91 60.28 42 3228 6317 1737194
Urticaria 87.32 60.28 52 3218 12189 1731322
Haemodynamic instability 85.77 60.28 27 3243 1310 1742201
Diabetes insipidus 85.44 60.28 21 3249 401 1743110
Vasoplegia syndrome 83.66 60.28 18 3252 184 1743327
Blood lactic acid increased 82.84 60.28 24 3246 875 1742636
Completed suicide 80.72 60.28 55 3215 16257 1727254
Anaphylactoid shock 80.26 60.28 16 3254 108 1743403
Medication error 80.11 60.28 36 3234 4707 1738804
Respiratory acidosis 79.86 60.28 22 3248 666 1742845
Respiratory failure 76.77 60.28 51 3219 14454 1729057
Hypertriglyceridaemia 75.82 60.28 24 3246 1185 1742326
Premature baby 75.27 60.28 30 3240 2912 1740599
Hypoventilation 75.25 60.28 20 3250 527 1742984
Post procedural fever 73.31 60.28 14 3256 73 1743438
Delirium 72.95 60.28 37 3233 6325 1737186
Renal failure 72.81 60.28 56 3214 19961 1723550
Brain oedema 72.64 60.28 27 3243 2169 1741342
Pulse absent 71.64 60.28 22 3248 982 1742529
Apnoea 71.55 60.28 24 3246 1425 1742086
Myoclonus 71.48 60.28 27 3243 2268 1741243
Multiple organ dysfunction syndrome 70.44 60.28 41 3229 9201 1734310
Respiratory distress 68.04 60.28 33 3237 5124 1738387
Dyskinesia 67.72 60.28 30 3240 3789 1739722
Product contamination 67.06 60.28 15 3255 186 1743325
Haemodialysis 64.57 60.28 26 3244 2590 1740921
Confusional state 63.46 60.28 53 3217 21225 1722286
Coma 62.81 60.28 35 3235 7227 1736284
Neonatal respiratory depression 62.77 60.28 12 3258 63 1743448
Torsade de pointes 61.71 60.28 21 3249 1303 1742208
Chromaturia 60.82 60.28 25 3245 2625 1740886
Arrhythmia 60.37 60.28 32 3238 5984 1737527

Pharmacologic Action:

SourceCodeDescription
ATC N01AX10 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Other general anesthetics
FDA PE N0000175975 General Anesthesia
FDA EPC N0000175681 General Anesthetic
MeSH PA D000777 Anesthetics
CHEBI has role CHEBI:38877 intravenous anaesthetic
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:35623 anticonvulsant
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Sedation in Intubated Patients indication
Sedation as Adjunct to Anesthesia indication
Apnea contraindication 1023001
Asthenia contraindication 13791008
Hypovolemia contraindication 28560003
Low blood pressure contraindication 45007003
Cerebral arteriosclerosis contraindication 65312002
Decreased respiratory function contraindication 80954004
Epilepsy contraindication 84757009 DOID:1826
Myocardial dysfunction contraindication 233928007
Disorder of lipid metabolism contraindication 267431006
Hypoxia contraindication 389086002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.8 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA A receptor alpha-2/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 4.95 CHEMBL CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 5.39 CHEMBL CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR EC50 5.70 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 5.22 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 4.91 WOMBAT-PK
Carbonic anhydrase 1 Enzyme IC50 4.71 WOMBAT-PK
Carbonic anhydrase 2 Enzyme IC50 4.01 WOMBAT-PK
Fatty-acid amide hydrolase 1 Enzyme IC50 4.28 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.42 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.03 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.46 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 5.12 DRUG MATRIX
Fatty-acid amide hydrolase 1 Enzyme IC50 4.85 CHEMBL
GABA-A receptor; anion channel Ion channel IC50 5.40 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel BLOCKER IC50 5.20 IUPHAR

External reference:

IDSource
4019500 VUID
N0000147620 NUI
C0033487 UMLSCUI
D00549 KEGG_DRUG
74674007 SNOMEDCT_US
4019500 VANDF
14179 MMSL
8782 RXNORM
387423006 SNOMEDCT_US
5372 MMSL
d00933 MMSL
003528 NDDF
4943 PUBCHEM_CID
CHEBI:44915 CHEBI
CHEMBL526 ChEMBL_ID
DB00818 DRUGBANK_ID
PFL PDB_CHEM_ID
YI7VU623SF UNII
5073 INN_ID
D015742 MESH_DESCRIPTOR_UI
5464 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PROPOFOL HUMAN PRESCRIPTION DRUG LABEL 1 0409-4699 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 0591-2136 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 0641-6194 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 0641-6195 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 0641-6196 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
propofol HUMAN PRESCRIPTION DRUG LABEL 1 25021-608 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 15 sections
Propofol Injectable Emulsion HUMAN PRESCRIPTION DRUG LABEL 1 43598-265 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 15 sections
Propofol Injectable Emulsion HUMAN PRESCRIPTION DRUG LABEL 1 43598-548 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 15 sections
Propofol Injectable Emulsion HUMAN PRESCRIPTION DRUG LABEL 1 43598-549 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 15 sections
Anesthesia S/I-60 HUMAN PRESCRIPTION DRUG LABEL 2 49836-024 KIT 10 mg None NDA 17 sections
Anesthesia S/I-40 HUMAN PRESCRIPTION DRUG LABEL 2 49836-025 KIT 10 mg None NDA 16 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 50090-4569 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 15 sections
PROPOFOL HUMAN PRESCRIPTION DRUG LABEL 1 51662-1293 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
PROPOFOL HUMAN PRESCRIPTION DRUG LABEL 1 51662-1470 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
PROPOFOL HUMAN PRESCRIPTION DRUG LABEL 1 51662-1471 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
PROPOFOL HUMAN PRESCRIPTION DRUG LABEL 1 52584-098 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Diprivan HUMAN PRESCRIPTION DRUG LABEL 1 52584-269 INJECTION, EMULSION 10 mg INTRAVENOUS NDA 11 sections
Propofol HUMAN PRESCRIPTION DRUG LABEL 1 52584-699 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
Diprivan HUMAN PRESCRIPTION DRUG LABEL 1 63323-269 INJECTION, EMULSION 10 mg INTRAVENOUS NDA 14 sections
Diprivan HUMAN PRESCRIPTION DRUG LABEL 1 65219-800 INJECTION, EMULSION 10 mg INTRAVENOUS NDA 14 sections